Ablation of CXCR3 in blood cells also reduced the levels of IL-10 and TGF-β in tumors (Fig. 5d), both of which have been shown to inhibit CRC development by dampening tumor-promoting inflammation [15, 17, 35, 36]. The gene discussed is CXCR3; the disease is neoplasm.